Skip to main content

Advertisement

SpringerLink
Log in

Reticulated platelets and antiplatelet therapy response in diabetic patients

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Increased platelet turnover and high level of reticulated platelets are associated with low response to antiplatelet therapy in diabetes mellitus type 2. This study evaluated association between percentage of reticulated platelets (%RP) and the response to antiplatelet therapy in patients with type 2 diabetes mellitus (T2DM). This prospective, pilot, case–control, clinical trial included 79 subjects stratified in three groups: group I included 30 patients with T2DM, group II included 34 non-diabetic patients and 15 healthy age and sex matched healthy volunteers were enrolled in control group. Platelet response to clopidogrel and aspirin was assessed by Multiplate® aggregometry analyzer. Individual response to dual antiplatelet therapy was estimated by the percentage of decrease in overall platelet aggregability (%DPA) obtained after antiplatelet therapy, calculated by presented formulas: %DPAadp = 100 × (1 − ADP/TRAP) and %DPAaspi = 100 × (1 − ASPI/TRAP). %RP was significantly higher in diabetics, than in non-diabetics, (3.17 ± 1.26 vs. 2.39 ± 1.56; p < 0.05). Significantly lower response to clopidogrel (31.55 ± 13.02 vs. 50.24 ± 11.38; p < 0.001) and aspirin (52.33 ± 22.67 vs. 64.31 ± 16.47; p < 0.05) therapy was observed in diabetics. %RP negatively correlated with response to clopidogrel therapy, but positively with metabolic profile indicators in diabetics (p < 0.05, all). Correlation of %RP with metabolic profile indicators and poor response to antiplatelet therapy suggest that altered metabolic profile can affect platelet turnover in T2DM leading to low responsiveness to antiplatelet therapy in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ferreiro JL, Gomez-Hospital JA, Angiolillo DJ (2009) Platelet abnormalities in diabetes mellitus. Diabetes Vasc Dis Res 7(4):251–259

    Article  Google Scholar 

  2. Angiolillo DJ, Shoemaker SB, Desai B et al (2007) Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study. Circulation 115:708–716

    Article  CAS  PubMed  Google Scholar 

  3. Gurbel PA, Tantry US (2007) Clopidogrel resistance? Thromb Res 120:311–321

    Article  CAS  PubMed  Google Scholar 

  4. Vlachojannis GJ, Dimitropoulos G, Alexopoulos D (2011) Clopidogrel resistance: current aspects and future directions. Hellenic J Cardiol 52:236–245

    PubMed  Google Scholar 

  5. Kakouros N, Rade JJ, Kourliouros A, Resar JR (2011) Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol. doi:10.1155/2011/742719

    PubMed Central  PubMed  Google Scholar 

  6. Ferreiro JL, Angiolillo DJ (2011) Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123:798–813

    Article  PubMed  Google Scholar 

  7. Giusti B, Gori AM, Marcucci R, Saracini C, Vestrini A, Abbate R (2010) Determination to optimize response to clopidogrel in acute coronary syndrome. Pharmacogenomics Pers Med 3:33–50

    Article  CAS  Google Scholar 

  8. Angiolillo DJ, Ferreiro JL (2010) Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions. Rev Esp Cardiol 63(1):60–76

    Article  PubMed  Google Scholar 

  9. Ibrahim H, Nadipalli S, DeLao T, Guthikonda S, Kleiman NS (2012) Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness. J Thromb Thrombolysis 33:137–142

    Article  CAS  PubMed  Google Scholar 

  10. Guthikonda S, Lev EI, Patel R et al (2007) Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 5:490–496

    Article  CAS  PubMed  Google Scholar 

  11. Guthikonda S, Alviar CL, Vaduganathan M et al (2008) Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. JACC 52(9):743–749

    Article  CAS  PubMed  Google Scholar 

  12. Hoffmann JJ (2014) Reticulated platelets: analytical aspects and clinical utility. Clin Chem Lab Med 52(8):1107–1117

    Article  CAS  PubMed  Google Scholar 

  13. Hoffman JJ, van den Broek NM, Curvers J (2013) Reference intervals of reticulated platelets and other platelet parameters and their associations. Arch Pathol Lab Med 137:1635–1640

    Article  Google Scholar 

  14. Wurtz M, Wulff LN, Grove EL, Kristensen SD et al (2012) Influence of renal function and platelet turnover on the antiplatelet effect of aspirin. Thromb Res 129:434–440

    Article  CAS  PubMed  Google Scholar 

  15. Larsen SB, Grove EL, Hvas A-M, Kristensen SD (2014) Platelet turnover in stable coronary artery disease—Influence of thrombopoietin and low-grade inflammation. PLoS One 9(1):e85566. doi:10.1371/journal.pone.0085566

    Article  PubMed Central  PubMed  Google Scholar 

  16. Lee EY, Kim SJ, Song YJ, Choi SJ, Song J (2013) Immature platelet fraction in diabetes mellitus and metabolic syndrome. Thromb Res 132:692–695

    Article  CAS  PubMed  Google Scholar 

  17. Gremmel T, Kopp CW, Seidinger D et al (2013) Impact of diabetes on platelet activation in different manifestations of atherosclerosis. Swiss Med Wkly 143:w13800

    PubMed  Google Scholar 

  18. Vaduganathan M, Alviar CL, Arikan ME (2008) Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am Heart J 156(5):1002-e1

    Article  Google Scholar 

Download references

Acknowledgment

The authors state no potential conflict of interest.

Author information

Authors and Affiliations

  1. Center for Laboratory Medicine, Clinical Center of Vojvodina, Novi Sad, Serbia

    Romana Mijovic, Zoran Stosic, Velibor Cabarkapa & Gorana Mitic

  2. Department of Cardiology, Health Center, Novi Sad, Serbia

    Nada Kovacevic

  3. Neurology Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia

    Marija Zarkov

  4. Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia

    Romana Mijovic, Marija Zarkov, Zoran Stosic, Velibor Cabarkapa & Gorana Mitic

Authors
  1. Romana Mijovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nada Kovacevic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marija Zarkov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zoran Stosic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Velibor Cabarkapa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gorana Mitic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Romana Mijovic.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mijovic, R., Kovacevic, N., Zarkov, M. et al. Reticulated platelets and antiplatelet therapy response in diabetic patients. J Thromb Thrombolysis 40, 203–210 (2015). https://doi.org/10.1007/s11239-014-1165-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-014-1165-3

Keywords

Search

Navigation